One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
1839 articles with Amgen
Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.
10/9/2018Affimed, based in Heidelberg, Germany, placed a clinical hold on its two AFM11 Phase I clinical trials. AFM11 is being evaluated in the trials for relapsed or refractory CD19 positive B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia.
10/9/2018Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association.
VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.
FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Approval of a More Convenient Once-Weekly Kd70 Regimen Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study
The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Emgality (galcanezumab-gnlm) for migraine prevention.
BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
First Approved Oncology Treatment From Amgen Astellas Joint Venture
Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer
Centrexion Therapeutics Corporation today announced that Andrew Partridge has been appointed Executive Vice President, Chief Commercial Officer of the company.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
9/21/2018A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service.
In the biotech hub area known as Pharm Country, the small state of Rhode Island often gets overlooked in favor of its larger neighbors, such as New York, New Jersey and Pennsylvania. But, the Ocean State is making some moves to enhance its image as a biotech hub, particularly in the wake of some ...
A new survey from Novartis, Amgen and Banner Alzheimer’s Institute, along with Alzheimer’s Disease International, shows that 91% of people from around the world believe medical research will result in a treatment for dementia.
Boehringer Ingelheim announced earlier this week that Christopher Corsico was leaving the company, effective December 31. Today it was announced that Corsico will join GSK to take on the new role of senior vice president of development.
A recent survey by the Pew Research Center found that 57 percent of Americans surveyed thought it was appropriate to use genetically engineered animals to grow organs for human transplants.
The U.S. Food and Drug Administration (FDA) approved Teva Pharmaceutical Industries’ Ajovy (fremanezumab) to prevent migraine on Friday, September 16.
As the Morgan Stanley Global Healthcare Conference runs from September 12 through 14, numerous biopharma companies are making presentations, updating their operations and pipeline activities. Here’s a look at some of the highlights.
9/13/2018Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.
CODA Biotherapeutics launched in South San Francisco with a $19 million Series A financing.
Once again, Amgen is accepting submissions for the 2018 Amgen-LabCentral Golden Ticket competition.
Amgen will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018, in London.